A study found that patients who took GLP-1 drugs saw a significant reduction in the risk of certain cancers, including esophageal, endometrial, liver and kidney cancer.
Why the obesity drug market is about to get a lot more crowded
The primetime special from Oprah Winfrey examined the rise of GLP-1 drugs like Ozempic and Mounjaro as well as the need to do away with obesity shaming.
Novo Nordisk’s Wegovy campaign focuses on how HCPs treat obesity
Telehealth firms have sought to cash in on the popularity of GLP-1 drugs for weight loss, but a hefty new entrant could prove a bigger windfall for Novo and Lilly in obesity.